Evidence map›Paper›PMID 18246028›Full record

ArticleMolecular vision2008

Effect of immunomodulation with anti-CD40L antibody on adenoviral-mediated transgene expression in mouse anterior segment.

J Cameron Millar, Iok-Hou Pang, Wan-Heng Wang, Yu Wang, Abbot F Clark

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. The Inducible TGFβ2 Ocular Hypertension Mouse Model.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  3. Viral Vector-Induced Ocular Hypertension in Mice.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Impaired TRPV4-eNOS signaling in trabecular meshwork elevates intraocular pressure in glaucoma.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  8. Article
  9. Article
  10. Inducible rodent models of glaucoma.Progress in retinal and eye research · 2020
    Review
  11. Article
  12. CRISPR-Cas9-based treatment of myocilin-associated glaucoma.Proceedings of the National Academy of Sciences of the United States of America · 2017
    Article
  13. Gene transfer to the outflow tract.Experimental eye research · 2017
    Review
  14. Review
  15. Gremlin Induces Ocular Hypertension in Mice Through Smad3-Dependent Signaling.Investigative ophthalmology & visual science · 2015
    Article
  16. Review
  17. BDNF treatment and extended recovery from optic nerve trauma in the cat.Investigative ophthalmology & visual science · 2013
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

J Cameron MillarAlcon Research, Ltd., Fort Worth, TX 76134, USA.
Iok-Hou Pang
Wan-Heng Wang
Yu Wang
Abbot F Clark
Alcon (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGene transduction using adenoviral vectors is an important research tool. To assess and optimize this technique for glaucoma research, we characterized green fluorescent protein (GFP) expression in the mouse eye after intraocular injection of adenoviral vector encoding GFP (Ad5.CMV-GFP) and evaluated the effect of anti-CD40L antibody administration on GFP expression.

methodsMice were injected with Ad5.CMV-GFP intracamerally (IC) or intravitreally (IVT) with or without anti-CD40L antibody treatment. GFP expression was assessed by in vivo fluorescence intensity with a standardized grading scale. Location of expression was analyzed histologically by fluorescence microscopy.

resultsIntraocular injection of Ad5.CMV-GFP induced titer-dependent expression of GFP in the anterior segment. In vivo fluorescence was detectable but low after IC injection. After IVT injection, fluorescence in the eye peaked at days 4-7 with a fluorescence grade of 3.0 +/-0.0 (mean +/-SEM, n=6; injection with 1x10(8) pfu vector). After day 7, GFP expression declined significantly. Treatment with anti-CD40L antibody increased fluorescence intensity after IC injection, and prolonged GFP expression in the IVT group. At day 43, fluorescence grades of the IVT group were 2.8 +/-0.7 (with anti-CD40L) and 1.2 +/-0.6 (without antibody). Three-Way ANOVA confirmed that GFP expression was significantly higher in the anti-CD40L than the no antibody group (p=0.013), significantly higher in the IVT than the IC group (p=0.003), and significantly higher in the high viral titer (1x10(8) pfu) than the low titer (1x10(7) pfu) group (p=0.010). Fluorescence microscopic examination of cross-sections of eyes indicated GFP expression in the trabecular meshwork (TM), corneal endothelium, and sporadically iris, ciliary body and lens epithelium.

conclusionsIntraocular injection of Ad5.CMV-GFP induced GFP expression in the mouse anterior segment, including the TM. Expression was more prominent after IVT injection than IC injection. Anti-CD40L antibody treatment increased both intensity and duration of GFP expression. These findings provide important and practical means to improve duration and efficiency of adenovirus-mediated transgene expression in the eye.

Indexed as

TransgenesAdenoviridaeAnimalsAnterior Eye SegmentAntibodiesCD40 LigandEyeFluorescenceGene ExpressionGenetic VectorsGreen Fluorescent ProteinsImmunologic FactorsInjectionsMaleMiceMice, Inbred BALB CAntibodiesCD40 Ligandgreen fluorescent protein, Aequorea victoriaGreen Fluorescent ProteinsImmunologic Factors

Identifiers

PMID18246028
PMCPMC2267727
OpenAlexW2237675506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.